Clinical perspectives for the use of melatonin as a chronobiotic and cytoprotective agent

Annals of the New York Academy of Sciences

Volumn 1057, Issue , 2005, Pages 327-336

  Cardinali, Daniel P ^a   Furio, Analía M ^a   Reyes, María P ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Aging; Alzheimer's disease; Chronobiotics; Circadian; Insomnia; Melatonin; Neuroprotection; Sleep

Indexed keywords

AMYLOID BETA PROTEIN; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; NEUROPROTECTIVE AGENT;

AGE; AGITATION; ALZHEIMER DISEASE; CHRONOBIOLOGY; CIRCADIAN RHYTHM; COGNITIVE DEFECT; CONFERENCE PAPER; CORTICAL SYNCHRONIZATION; DETERIORATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; GENE EXPRESSION; HUMAN; HYPOTHALAMUS; INSOMNIA; NONHUMAN; OSCILLATION; SLEEP; SLEEP WAKING CYCLE; SLOW WAVE SLEEP; SUPRACHIASMATIC NUCLEUS; TREATMENT OUTCOME;

EID: 32244442798     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1356.025     Document Type: Conference Paper

References (87)

1. GACHON, F. et al. 2004. The mammalian circadian timing system: from gene expression to physiology. Chromosoma 113: 103-112.
2. SAPER, C.B. et al. 2005. The hypothalamic integrator for circadian rhythms. Trends Neurosci. 28: 152-157.
3. DIJK, D.J. & J.F. DUFFY. 1999. Circadian regulation of human sleep and age-related changes in its timing, consolidation, and EEG characteristics. Ann. Med. 31: 130-140.
4. TZISCHINSKY, O. et al. 1993. The association between the nocturnal sleep gate and nocturnal onset of urinary 6-sulfatoxymelatonin. J. Biol. Rhythms 8: 199-209.
5. ZHDANOVA, I.V. et al. 1996. Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans. Sleep 19: 423-431.
6. CARSKADON, M.A. et al. 1982. Sleep fragmentation in the elderly: relationship to day-time sleep tendency. Neurobiol. Aging 3: 321-327.
7. IGUCHI, H. et al. 1982. Age-dependent reduction in serum melatonin concentrations in healthy human subjects. J. Clin. Endocrinol. Metab. 55: 27-29.
8. DORI, D. et al. 1994. Chrono-neuroendocrinological aspects of physiological aging and senile dementia. Chronobiologia 21: 121-126.
9. GIROTTI, L. et al. 2000. Low urinary 6-sulphatoxymelatonin levels in patients with coronary artery disease. J. Pineal Res. 29: 138-142.
10. SIEGRIST, C. et al. 2001. Lack of changes in serum prolactin, FSH, TSH, and estradiol after melatonin treatment in doses that improve sleep and reduce benzodiazepine consumption in sleep-disturbed, middle-aged, and elderly patients. J. Pineal. Res. 30: 34-42.
11. MISHIMA, K. et al. 2000. Supplementary administration of artificial bright light and melatonin as potent treatment for disorganized circadian rest-activity and dysfunctional autonomic and neuroendocrine systems in institutionalized demented elderly persons. Chronobiol. Int. 17: 419-432.
12. LUBOSHITZKY, R. et al. 2001. Actigraphic sleep-wake patterns and urinary 6-sulfatoxymelatonin excretion in patients with Alzheimer's disease. Chronobiol. Int. 18: 513-524.
13. MISHIMA, K. et al. 2001. Diminished melatonin secretion in the elderly caused by insufficient environmental illumination. J. Clin. Endocrinol. Metab. 86: 129-134.
14. HAIMOV, I. et al. 1994. Sleep disorders and melatonin rhythms in elderly people. Br. Med. J. 309: 167.
15. KARASEK, M. et al. 2002. Future of melatonin use in the therapy. Neuroendocrinol. Lett. 23: 118-121.
16. KARASEK, M. 2004. Melatonin, human aging, and age-related diseases. Exp. Gerontol. 39: 1723-1729.
17. DAWSON, D. & S.M. ARMSTRONG. 1996. Chronobiotics-drugs that shift rhythms. Pharmacol. Ther. 69: 15-36.
18. CARDINALI, D.P. & P. PÉVET. 1998. Basic aspects of melatonin action. Sleep Med. Rev. 2: 175-190.
19. KENNAWAY, D.J. & H. WRIGHT. 2002. Melatonin and circadian rhythms. Curr. Top. Med. Chem. 2: 199-209.
20. REITER, R.J. 1980. The pineal and its hormones in the control of reproduction in mammals. Endocr. Rev. 1: 109-131.
21. WURTMAN, R.J. & I. ZHDANOVA. 1995. Improvement of sleep quality by melatonin. Lancet 346: 1491.
22. MONTI, J.M. et al. 1999. Polysomnographic study of the effect of melatonin on sleep in elderly patients with chronic primary insomnia. Arch. Gerontol. Geriatr. 28: 85-98.
23. GUERRERO, J.M. & R.J. REITER. 2002. Melatonin-immune system relationships. Curr. Top. Med. Chem. 2: 167-179.
24. ESQUIFINO, A.I. et al. 2004. Circadian organization of the immune response: a role for melatonin. Clin. Appl. Immunol. Rev. 4: 423-433.
25. BLASK, D.E. et al. 2002. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr. Top. Med. Chem. 2: 113-132.
26. SCHEER, F.A. et al. 2004. Daily night time melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 43: 192-197.
27. DUBOCOVICH, M.L. et al. 1999. Molecular pharmacology and function of melatonin receptor subtypes. Adv. Exp. Med. Biol. 460: 181-190.
28. KUNZ, D. 2004. Chronobiotic protocol and circadian sleep propensity index: new tools for clinical routine and research on melatonin and sleep. Pharmacopsychiatry 37: 139-146.
29. SRINIVASAN, V. 1997. Melatonin, biological rhythm disorders, and phototherapy. Indian J. Physiol. Pharmacol. 41: 309-328.
30. REITER, R.J. et al. 2005. When melatonin gets on your nerves: its beneficial actions in experimental models of stroke. Exp. Biol. Med. 230: 104-117.
31. LEWY, A.J. et al. 1998. The human phase response curve (PRC) to melatonin is about 12 hours out of phase with the PRC to light. Chronobiol. Int. 15: 71-83.
32. MACCHI, M.M. & J.N. BRUCE. 2004. Human pineal physiology and functional significance of melatonin. Front. Neuroendocrinol. 25: 177-195.
33. ALLEGRA, M. et al. 2003. The chemistry of melatonin's interaction with reactive species. J. Pineal Res. 34: 1-10.
34. 1-acetyl-5-methoxykynuramine (AMK): scavenging of free radicals and prevention of protein destruction. Redox. Rep. 8: 205-213.
35. DUBOCOVICH, M.L. et al. 2000. Melatonin receptors. In The IUPHAR Compendium of Receptor Characterization and Classification, 2nd Edition. IUPHAR, Ed.: 271-277. IUPHAR Media. London.
36. WIESENBERG, I. et al. 1998. The potential role of the transcription factor RZR/ROR as a mediator of nuclear melatonin signaling. Rest. Neurol. Neurosci. 12: 143-150.
37. ANTON-TAY, F. et al. 1998. Modulation of the subcellular distribution of calmodulin by melatonin in MDCK cells. J. Pineal Res. 24: 35-42.
38. MAILLIET, F. et al. 2004. Organs from mice deleted for NRH: quinone oxidoreductase 2 are deprived of the melatonin binding site MT3. FEBS Let. 578: 116-120.
39. CARDINALI, D.P. et al. 1997. Melatonin site and mechanism of action: single or multiple? J. Pineal Res. 23: 32-39.
40. LEON, J. et al. 2004. Melatonin and mitochondrial function. Life Sci. 75: 765-790.
41. DUBOCOVICH, M.L. et al. 2003. Molecular pharmacology, regulation, and function of mammalian melatonin receptors. Front. Biosci. 8: 1093-1108.
42. LAVIE, P. 2001. Sleep-wake as a biological rhythm. Annu. Rev. Psychol. 52: 277-303.
43. SKENE, D.J. et al. 1999. Melatonin in circadian sleep disorders in the blind. Biol. Signals Recept. 8: 90-95.
44. CARDINALI, D.P. et al. 2002. A double blind-placebo controlled study on melatonin efficacy to reduce anxiolytic benzodiazepine use in the elderly. Neuroendocrinol. Lett. 23: 55-60.
45. CARDINALI, D.P. et al. 2002. The use of melatonin in Alzheimer's disease. Neuroendocrinol. Lett. 23: 20-23.
46. CARDINALI, D.P. et al. 2002. A multifactorial approach employing melatonin to accelerate resynchronization of sleep-wake cycle after a 12 time-zone westerly transmeridian flight in elite soccer athletes. J. Pineal Res. 32: 41-46.
47. ARENDT, J. 2003. Importance and relevance of melatonin to human biological rhythms. J. Neuroendocrinol. 15: 427-431.
48. BEAUMONT, M. et al. 2004. Caffeine or melatonin effects on sleep and sleepiness after rapid eastward transmeridian travel. J. Appl. Physiol. 96: 50-58.
49. McCURRY, S.M. et al. 2000. Treatment of sleep disturbance in Alzheimer's disease. Sleep Med. Rev. 4: 603-628.
50. GIUBILEI, F. et al. 2001. Altered circadian cortisol secretion in Alzheimer's disease: clinical and neuroradiological aspects. J. Neurosci. Res. 66: 262-265.
51. HARPER, D.G. et al. 2001. Differential circadian rhythm disturbances in men with Alzheimer disease and frontotemporal degeneration. Arch. Gen. Psych. 58: 353-360.
52. STOPA, E.G. et al. 1999. Pathologic evaluation of the human suprachiasmatic nucleus in severe dementia. J. Neuropathol. Exp. Neurol. 58: 29-39.
53. SKENE, D.J. & D.F. SWAAB. 2003. Melatonin rhythmicity: effect of age and Alzheimer's disease. Exp. Gerontol. 38: 199-206.
54. MISHIMA, K. et al. 1999. Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep-waking. Biol. Psych. 45: 417-421.
55. UCHIDA, K. et al. 1996. Daily rhythm of serum melatonin in patients with dementia of the degenerate type. Brain Res. 717: 154-159.
56. LIU, R.Y. et al. 1999. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon 4/4 genotype. J. Clin. Endocrinol. Metab. 84: 323-327.
57. OHASHI, Y. et al. 1999. Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer's type. Biol. Psych. 45: 1646-1652.
58. FERRARI, E. et al. 2000. Pineal and pituitary-adrenocortical function in physiological aging and in senile dementia. Exp. Gerontol 35: 1239-1250.
59. CARDINALI, D.P. et al. 2002. The use of melatonin in Alzheimer's disease. Neuroendocrinol. Lett. 23: 20-23.
60. WU, Y.H. et al. 2003. Molecular changes underlying reduced pineal melatonin levels in Alzheimer's disease: alterations in preclinical and clinical stages. J. Clin. Endocrinol. Metab. 88: 5898-5906.
61. SAVASKAN, E. et al. 2005. Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease. J. Pineal Res. 38: 10-16.
62. FAINSTEIN, I. et al. 1997. Effects of melatonin in elderly patients with sleep disturbance. A pilot study. Curr. Ther. Res. 58: 990-1000.
63. JEAN-LOUIS, G. et al. 1998. Melatonin effects on sleep, mood, and cognition in the elderly with mild cognitive impairment. J. Pineal Res. 25: 177-183.
64. COHEN-MANSFIELD, J. et al. 2000. Melatonin for treatment of sundowning in elderly persons with dementia. Arch. Gerontol. Geriatr. 31: 65-76.
65. BRUSCO, L.I. et al. 1998. Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease. Neuroendocrinol. Lett. 19: 111-115.
66. BRUSCO, L.I. et al. 1998. Monozygotic twins with Alzheimer's disease treated with melatonin: case report. J. Pineal Res. 25: 260-263.
67. ASAYAMA, K. et al. 2003. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive, and noncognitive functions in Alzheimer-type dementia. J. Nippon Med. Sch. 70: 334-341.
68. MAHLBERG, R. et al. 2004. Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer's disease: an open-label pilot study using actigraphy. J. Clin. Psychopharmacol. 24: 456-459.
69. SINGER, C. et al. 2003. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 26: 893-901.
70. VAN COEVORDEN, A. et al. 1991. Neuroendocrine rhythms and sleep in aging men. Am. J. Physiol. 260: 651-661.
71. WANG, Y.P. et al. 2004. Melatonin ameliorated okadaic-acid induced Alzheimer-like lesions. Acta Pharmacol. Sin. 25: 276-280.
72. BENITEZ-KING, G. et al. 2003. Melatonin prevents cytoskeletal alterations and oxidative stress induced by okadaic acid in NlE-115 cells. Exp. Neurol. 182: 151-159.
73. LI, X.C. et al. 2005. Effect of melatonin on calyculin A-induced tau hyperphosphorylation. Eur. J. Pharmacol. 510: 25-30.
74. FURIO, A.M. et al. 2002. Effect of melatonin on changes in locomotor activity rhythm of Syrian hamsters injected with beta amyloid peptide 25-35 in the suprachiasmatic nuclei. Cell. Mol. Neurobiol. 22: 699-709.
75. PAPPOLLA, M.A. et al. 1997. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J. Neurosci. 17: 1683-1690.
76. PAPPOLLA, M.A. et al. 1999. Alzheimer beta protein-mediated oxidative damage of mitochondrial DNA: prevention by melatonin. J. Pineal Res. 27: 226-229.
77. PAPPOLLA, M.A. et al. 2000. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease. J. Neural Transm. 107: 203-231.
78. PAPPOLLA, M.A. et al. 2002. The neuroprotective activities of melatonin against the Alzheimer beta-protein are not mediated by melatonin membrane receptors. J. Pineal Res. 32: 135-142.
79. FENG, Z. et al. 2004. Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. J. Pineal Res. 37: 129-136.
80. KAWARABAYASHI, T. et al. 2001. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21: 372-381.
81. CLAPP-LILLY, K.L. et al. 2001. Melatonin reduces interleukin secretion in amyloid-beta stressed mouse brain slices. Chem. Biol. Interact. 134: 101-107.
82. HARRIS, F.M. et al. 2004. Astroglial regulation of apolipoprotein E expression in neuronal cells. Implications for Alzheimer's disease. J. Biol. Chem. 279: 3862-3868.
83. MALCHIODI-ALBEDI, F. et al. 2001. Astrocytes contribute to neuronal impairment in beta A toxicity increasing apoptosis in rat hippocampal neurons. Glia 34: 68-72.
84. FENG, Z. & J.T. ZHANG. 2004. Protective effect of melatonin on beta-amyloid-induced apoptosis in rat astroglioma C6 cells and its mechanism. Free Radic. Biol. Med. 37: 1790-1801.
85. CARDINALI, D.P. et al. 2003. Melatonin effects on bone: experimental facts and clinical perspectives. J. Pineal Res. 34: 81-87.
86. REYES TOSO, C. et al. 2002. Vascular reactivity in diabetic rats: effect of melatonin. J. Pineal Res. 33: 81-86.
87. REYES TOSO C. et al. 2004. Effect of melatonin on vascular reactivity in pancreatectomized rats. Life Sci. 74: 3085-3092.